Get the StoQuant digest — free

Free StoQuant digest by email. No account needed. See today's research picks.

Subscribe free

GRFS vs NAMS — Stock Comparison

Compare GRFS and NAMS side-by-side on StoQuant: GRFS Q-Score 38 vs NAMS 24; analyst signal 54 vs 79. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.

Side-by-side snapshot

• GRFS — Grifols, S.A. · Health Care · market cap $6.40B · Q-Score verdict Sell (38.0, grade D) · analyst signal 54/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: valuation 43/100, analyst consensus 23/100 · weakest signals: technicals 22/100, AI Alpha (gem) 2/100. Full GRFS research.
• NAMS — NewAmsterdam Pharma Company N.V. · Health Care · market cap $2.30B · Q-Score verdict Strong Sell (24.0, grade F) · analyst signal 79/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: competitive moat 97/100, analyst consensus 88/100 · weakest signals: technicals 7/100. Full NAMS research.

What you can compare

• Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
• Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
• Insider activity: Cluster scores and recent Form 4 buying.
• Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
• Strategic edges: Competitive moat and durable advantage analysis.
• Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
• Macro context: Market regime and sector rotation alignment.

Deep dive: GRFS research · NAMS research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →